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RA diagnoses were most prevalent in the Marmara region (38%), followed by Ae-
gean (20%), Central Anatolia (21%), and Mediterranean (15%). Nearly 40% of RA
patients had at least one cardiovascular, diabetic, respiratory or allergy comorbid
condition prior to diagnosis. 5% of patients were hospitalized and 42% had at least
one outpatient visit during the pre-index period. Most patients were prescribed
non-COX inhibitors (78%) and immunosuppressants (71%), and 11% of patients
were prescribed disease-modifying anti-rheumatic drugs (DMARDs). Few patients
(1%) had surgery prior to diagnosis. The total annual cost (a2,386) was comprised of
mainly pharmacy (a1,747), followed by outpatient (a360), and inpatient costs (a252),
and an average copay of 27a. Prior comorbid conditions including diabetes, respi-
ratory disease as well as hospitalization, glucocorticoid and DMARD use signifi-
cantly contributed to annual health care costs, unlike gender and age.
CONCLUSIONS: Annual costs of RA patients are significantly lower in Turkey rel-
ative to other countries in Europe, yet, pharmaceutical expenditures cover a sig-
nificant portion of the overall cost. Comparative effectiveness studies are needed to
further decrease pharmaceutical expenditures for RA treatment.
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OBJECTIVES: To determine indirect costs of rheumatoid arthritis (RA) due to work
loss, RA-related consultations, additional investments and caregivers in patients
who utilized public health care facility services in Turkey. Association between
indirect cost and disease activity scores such as Global Disease Activity (GDA),
EuroQoL health status (EQ-5D), visual analog scale (VAS), Health Assessment Ques-
tionnaire (HAQ) and the Routine assessment of patient index data (RAPID-3) were
also analyzed. METHODS: This cross-sectional study was performed in 10 univer-
sity rheumatology centers. Eligible patients were age18, diagnosed with RA for at
least 12 months according to the American College of Rheumatology (ACR) 1987
criteria. We assessed relevant indirect cost variables, activities associated with
indirect costs, and actual costs. Multivariate regression determined variables as-
sociated with higher indirect costs. Pearson correlation examined the association
between indirect costs and disease activity scores. RESULTS:A total of 698 patients
(82% female; mean age: 51.2  13.17 standard deviation [SD]) were questioned
regarding indirect RA costs. 14% were employees, of which 62% had employer
permission to miss work (average 27 days annually) due to RA, costing patients an
average €480 annually due to workday loss. 5.4% of patients had other RA-related
consultations not covered by insurance (acupuncture, homeopathic, other), bring-
ing their average annual burden to €1,600. 6.5% of RA patients incurred additional
RA-related costs (e.g. need for new car, apartment, special equipment), spending
an additional €1,640 in 1 year. 13.7% of patients required caregivers. The average
annual out-of-pocket amount paid to caregivers was €624. Multivariate regression
showed that age and gender were not significantly related to indirect costs. Pa-
tients needing caregivers reported significantly higher GDA, VAS, HAQ, RAPID-3
and lower EQ-5D scores. CONCLUSIONS: Indirect RA-related costs in Turkey are
significant. Comparative effectiveness studies on RA treatment should include di-
rect and indirect costs.
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OBJECTIVES: To estimate risk-adjusted health care costs and identify associated
risk factors for ankylosing spondylitis (AS) expenditures in Turkey using real-world
data. METHODS: This study used research-identified data from a system that pro-
cesses claims for all Turkish health insurance funds. Incident cases of adult AS
patients with two AS visits at least 60 days apart, identified between June 1, 2010
and December 31, 2010, were required to have no AS diagnosis before June 1, 2010,
with at least 1 year of continuous enrollment for the baseline and follow-up years.
Pharmacy, outpatient and inpatient claims were compiled over the study period for
the selected patients. RESULTS: Among 603 patients (mean age: 38.74; female:
44%), 58% were age 18-39, 39% were 40-64 years and 3% were age 65 or older. AS
diagnosis was most prevalent in the Marmara region (49%), followed by Central
Anatolia (22%), Aegean (13%), and Mediterranean (7%). Nearly 25% of AS patients
had at least one cardiovascular, diabetic, respiratory, allergy, Crohn’s disease and
rheumatoid arthritis comorbid condition prior to diagnosis. Most patients were
prescribed non-COX inhibitors (67%) and 7% of patients were prescribed disease-
modifying anti-rheumatic drugs (DMARDs). The total annual cost (a2,254) was com-
prised of mainly pharmacy (a1,738), followed by outpatient (a331), and inpatient
costs (a162), and an average copay of a23. Prior comorbid conditions including dia-
betes, respiratory disease as well as hospitalization, glucocorticoid and DMARD use
significantly contributed to annual health care costs, unlike gender and age.
CONCLUSIONS: Annual costs of AS patients are significantly lower in Turkey rela-
tive to other countries in Europe, yet, pharmaceutical expenditures cover a signif-
icant portion of the overall cost. Comparative effectiveness studies are needed to
further decrease pharmaceutical expenditures for AS treatment.
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OBJECTIVES: International pharmacoeconomic studies suggest Health Assess-
ment Questionnaire (HAQ) as an important predictor of evaluation both direct and
productivity costs of rheumatoid arthritis (RA). Costs are supposed to increase with
increasing HAQ value. Therefore, we calculated direct (from health insurances
perspective) and productivity costs for five groups of patients according to their
HAQ (0.6, 0.6-1.1, 1.1-1.6, 1.6-2.1, 2.1) to confirm this assumption also in the
Slovak Republic. METHODS: This calculation was based on a retrospective cross-
sectional study. We included 119 patients with rheumatoid arthritis, aged 18-84
years either at working status, part-time disabled or full-time disabled. We used
prevalence-based cost-of-illness method type bottom-up, retrospectively review-
ing individual patient’s medical record. For calculation of productivity costs we
excluded patients older than 63 years of age (retirement pensioners). We used
friction costs approach (FCA) with defined friction period of 130 workdays, based on
patients’ absenteeism due to RA. Productivity of part-time-disabled and full-time
disabled patients were assumed to be deteriorated by 50% and 70%, respectively,
based on the Slovak law on pension insurance. The height of average monthly
income in year 2010, €769 was used as denominator. Costs were expressed as mean
value per one patient with RA in each of the HAQ-group. RESULTS: Average pa-
tients= age was 49.5 years; average time from diagnosis was 12.3 years with mean
HAQ score 1.4 and mean DAS28 5.0. Mean annual medical direct costs, for each
HAQ-group, were €516, €468, €943, €1676, and €1466, respectively. Mean annual
indirect costs associated with productivity loss were €224, €1600, €1847, €2109, and
€2030, respectively. CONCLUSIONS: Direct and productivity costs for patients with
rheumatoid arthritis are closely related to the height of HAQ score. Total (direct and
productivity) annual mean costs were €2576.
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OBJECTIVES: To examine the resource utilization and direct costs of care associ-
ated with use of biologic agents therapy among prevalent rheumatoid arthritis (RA)
patients based on retrospective health care claims data. The database (EGB) is a
1/97 representative sample of the national claim database covering the whole
French population. METHODS: RA patients were identified as adults (age 18)
benefiting from full coverage (ALD eligibility criteria) for RA (ICD-10 M05-06) on
January 1, 2009 and still alive on December 31st, 2010. Biologics treated patients
(BTP) were defined as RA patients with 1 claim for biologics in 2010. All health
expenses were assessed from the payer’s perspective. A log-linear generalised
model was used to adjust the costs in comparing BTP versus patients not treated by
biologics (BNP). RESULTS: A total of 1,234 RA patients were identified of whom 199
(16.0%) were treated with biologics (BTP) including TNF inhibitors in 85% of cases. In
comparing patients not treated by biologics (BNP) versus BTP, the proportion of
male patients (24.1% versus 24.1% p0.99) nor the time since registration for RA
coverage (8.5 versus 9.0 years p0.33) were significantly different but BTP patients
were significantly younger 55.2 years  12.9 versus 64.1 years  14.5 (p0.0001).
The unadjusted per capita annual expenses of BTP were three times higher than in
BNP (15,581 € versus 4,892 € - p0.0001). Drug costs were respectively 8,477 € (54.4%
of total) versus 1,151€ (23.5% of total) (p 0.0001) and in-patient care 4,878 € (31.3%
of total) versus 1,696 € (34.7% of total) (p 0.0001). After adjustment for age, the
mean annual extra cost of patients on biologics was in the range 11,000 € - 12,000 €.
CONCLUSIONS: When compared to similar data prior to the era of biologics, the
structure of medical expenses in RA patients has shifted from in-patient care to-
wards drugs.
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OBJECTIVES: To examine the resource utilization and direct costs of care of prev-
alent rheumatoid arthritis (RA) patients using retrospective health care claims
data. METHODS: The EGB is a national representative 1/97 sample of individuals
covered by the French Health Insurance. Individuals presenting with RA (ICD-10 codes:
M05-06) can be identified in the database because they benefit from a full coverage. All
items of health care utilization and associated costs were assessed from the Health
Insurance perspective for 2010. The economic burden of RA was estimated by com-
paring medical expenses in the RA adult (18 years) population to a control group
matched on sex and age and using non parametric Mann-Whitney tests. RESULTS:
A total number of 1,296 RA patients were identified, i.e. a crude prevalence rate of
3.47/1000. The mean age was 63.3 years ( 14.8) and the sex ratio H/F was 0.33. A
proportion of 39.4% of patients benefitted from additional full coverage for other
co-morbibities, severe Hypertension (7.8%), NIDD (6.1%), Ischemic Heart Disease
(3%), Depression (1.9%) being the most frequent. Annual medical costs of the RA
population were 2 times higher than control (6,607 € versus 3,248 € p0.0001). The
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main contributors to this extra cost were pharmaceuticals (1,687€; 50.2%) and
in-patient care (903€; 26.9%). The proportion of patients with other co-morbidities
leading to full coverage was not significantly different in the RA group versus
control (39.4% versus 41.8% p0.134) although Hypertension (7.8% versus 6.7%
p0.44) was significantly more frequent. Differences for Ischemic Heart Disease
(3.0% versus 2.5%) and Depression (1.9% versus 1.4%) were positive but did not
reach statistical significance.CONCLUSIONS:The economic burden of RA in France
to the health care system is significant and apparently not associated to the pres-
ence of severe co-morbidity as identified in this database.
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OBJECTIVES: There are 6,000 hip fractures annually in Finland with a population of
5.4 million. These elderly patients (average 80y) almost always require surgery.
Among elderly, 14% are using warfarin, and the anticoagulation effect should be
reversed prior to surgery. The four approaches commonly used are: cessation of
warfarin therapy, administration of vitamin-K, Fresh Frozen Plasma (FFP) or Pro-
thrombin Complex Concentrate (PCC). These approaches have different onset
times and thus, the choice of the method used influences the delay before the
surgery can safely be performed. Delay of the operation increases the number of
preoperative hospital days, and is associated with increased mortality. PCC acts as
an antidote, and thus enables immediate operation. METHODS: There were 232
patients with acute hip fracture in Kuopio University Hospital (KUH) in 2009 with a
30 days mortality of 18 patients and delay of 16 operations. Patients in need for
warfarin reversal were estimated, as well as additional hospital days caused by the
possible delay of surgery. Medication, laboratory costs, and cost of hospitalization
due to the delay were estimated for a one year perspective. Mortality rate w/wo
delay was estimated. RESULTS: There were estimated to be 29 patients with acute
hip fracture requiring warfarin reversal in KUH annually. Among these patients,
the reversal of anticoagulation with FPP, vitamin K, or cessation of warfarin leads to
30, 30 and 116 additional hospital days per year compared to PCC. The total costs
were 22 700€, 10200 €, 156 900€ and 20 300€ with FFP, vitamin-K, cessation of war-
farin and PCC, respectively. Mortality rate was estimated to be 10.6% and 7.5%
w/wo delay, respectively. CONCLUSIONS: Delay of the acute surgical intervention
increases health care costs. The use of antidote (PCC) decreases this delay among
warfarin users, and may lead to cost savings and decrease in mortality.
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OBJECTIVES: Postoperative thrombosis is a common complication after major or-
thopaedic surgery. Standard prophylaxis is done with subcutaneous injections of
low molecular heparin. Oral anticoagulants became available for this indication in
the last years. It was the aim of this study to develop a modelling matrix consider-
ing all types of costs in order to allow for a cost-benefit-analysis comparing anti-
coagulants in the post-operative setting. METHODS: This study is a prospective,
comparing clinical observation study. 90 patients after total hip/knee replacement
were included. Quality of life (QOL) was measured by an specific score (PACT-Q®).
Also the compliance was analyzed (Morisky). Clinical/labdata as well as informa-
tion on occurrence and reason of readmittance to the hospital were collected. This
analysis evaluates the cost-benefit-ratio of the oral anticoagulant rivaroxaban
compared with subcutaneous low molecular weight heparin certoparin-sodium
from the German patients’ and society‘s perspective. RESULTS: For this study a
new method was developed. The result is a matrix, which calculates the corrected
total costs (Cc) by multiplication of direct costs (CD) with a factor FQOL represent-
ing QOL. FQOLis the difference between optimal and actual quality of life (in). By
this method, the effect of QOL and compliance on total costs and on the value of a
therapy becomes visible. By application of two anticoagulants it became apparent,
that the corrected costs for rivaroxaban where lower (22,1%) than its direct costs,
resulting in a sum advantage for the innovative drug, although direct costs were
higher (9,7%) for the oral drug.CONCLUSIONS:Medicaments enter the market with
mostly higher prices compared to the standard. The payers should evaluate, if the
more expensive pharmaceutical product saves costs during the therapeutical path-
way or if the result generates a higher quality of life for the patients which could
mean better compliance with less costs for following treatments.
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OBJECTIVES: Ankylosing spondylitis (AS) is an inflammatory disease of unknown
cause. The study evaluated the cost effectiveness of adalimumab vs. placebo, goli-
mumab vs. placebo, and adalimumab vs. golimumab in patients with active AS
from the Italian payer perspective. METHODS: A cohort Markov model was devel-
oped to estimate over a time horizon of 40 years costs and QALYs associated with
adalimumab or golimumab, when used according to existing treatment guidelines.
The analysis was based on data from two Phase III studies of adalimumab and
golimumab in active AS (combined ATLAS and Canadian trials, and GO-RAISE,
respectively). Using the trial information, patients were categorized into respond-
ers and non-responders at week 12. In the base case model, response was defined
using the ASAS 20 criterion. A univariate and probabilistic sensitivity analyses was
performed to assess the robustness of the results. RESULTS: In the base case ada-
limumab therapy estimate 1.29 more discounted QALYs per patient vs. conven-
tional therapy anda total net cost (adalimumab vs. placebo) of € 43,617 per patient
resulting in an ICER of € 33,704/QALY. The analysis performed between golimumab
vs placebo led to ICER of € 39,149 per QALY gained. Comparing adalimumab to
golimumab, adalimumab resulted in 0.12 additional QALYs and € 2,350 in savings
and is therefore considered dominant. These results were sensitive to whether the
proportion of responders were adjusted for age or non-response imputation be-
tween trials and the proportion of patients who weighed over 100 kg and would
therefore require a higher dose of golimumab to reach similar effectiveness. The
results further favored adalimumab when indirect costs were included.
CONCLUSIONS: From the Italian payer and societal (in sensitivity analysis) per-
spectives, treatment of AS with adalimumab is cost saving and more effective
compared to golimumab, and thus is dominant versus golimumab, when used
according to the general treatment guidelines.
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OBJECTIVES: ADACTA trial (Gabay C et al EULAR June 2012) showed that tocili-
zumab (TCZ) monotherapy was superior to adalimumab (ADA) monotherapy in
reducing signs and symptoms of adult rheumatoid arthritis (RA) patients who were
either intolerant to methotrexate (MTX) or for whom continued MTX treatment
was inappropriate. The aim of the current study was to develop a cost-effective-
ness analysis of TCZ vs. ADA in MTX-intolerant/contraindicated patients.
METHODS: Economic evaluation based on ADACTA study was conducted to esti-
mate the incremental cost-effectiveness ratio (ICER) of TCZ vs. ADA. Time horizon
was 24 weeks. Patient’s response in the model was measured through ACR re-
sponse (ACR20/ACR50/ACR70) and DAS28 remission. Results were presented as
incremental cost of TCZ vs. ADA per response. The analysis was conducted from
the perspective of the Spanish National Healthcare System, considering drug costs.
Unitary costs (€, 2012) were obtained from a Spanish database. Simple univariate
sensitivity analyses were performed. RESULTS: ACR20 response rates were
achieved in 65% and 49.4% in the TCZ and ADA group respectively (p0.01). ACR50
response rates were achieved in 47.2% and 27.8% in TCZ and ADA group (p0.01)
and ACR70 response rates in 32.5% and 17.9% in TCZ and ADA group (p0.01)
respectively. DAS28 Remission was achieved in 39.9% and 10.5% in TCZ and ADA
group (p0.0001). Treatment with TCZ provided better results in cost per response
than ADA over 24 weeks in terms of ACR response (ACR20 €8,105 and €11,553;
ACR50 €11,162 and €20,382; ACR70 €15,965 and €31,705) and DAS 28 remission
€13,509 and €54,352 respectively. TCZ was dominant over ADA in ACR response and
DAS28 remission. Sensitivity analysis confirmed the stability of the results.
CONCLUSIONS: The results of this analysis suggest that TCZ monotherapy repre-
sents an efficient and cost-effective strategy vs. ADA in Spain, for treating RA
patients who are MTX intolerant/contraindicated.
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OBJECTIVES: The introduction of new biologic treatments has therefore dramati-
cally changed the therapeutic management of PsAThe objective of this study was
to determine the cost-effectiveness of biologic drugs for patients with moderate to
severe psoriatic arthritis (PsA) in Italy. METHODS: ACR and PASI response rates
from 8 randomized controlled trials were considered as indicators for clinical effi-
cacy. Short-term efficacy was based on relative probabilities of achieving ACR20
and PASI75 response in a meta-analysis. Published evidence and assumptions
were used to predict long-term efficacy. Treatment benefits were determined by
the relationship between HAQ and PASI with the EuroQoL 5D. Costs included drug
acquisition, administration, monitoring and hospitalisation. ICERs were calculated
by ordering treatments by QALYs, and comparing each treatment sequentially. A
40 year time horizon was considered, looking at the Italian perspective. RESULTS:
After palliative care, Golimumab was estimated to produce the next most QALYs.
However, in comparison to Golimumab, Adalimumab was estimated to provide an
additional 0.074 QALYs at less cost and so is a dominating strategy. In comparison
to palliative care, Adalimumab had an ICER of € 15,970 per QALY. Etanercept was
estimated to give similar additional QALYs and costs to Adalimumab. Infliximab
was estimated to provide 0.057 QALYs more than Etanercept, but this came with €
6,938 additional cost, giving Infliximab an ICER of € 121,806 per QALY versus Etan-
ercept. A number of one-way sensitivity analyses were performed finding various
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